Tamoxifen Malabsorption after Roux-en-Y Gastric Bypass Surgery: Case Series and Review of the Literature

Pharmacotherapy

Volumn 30, Issue 2, 2010, Pages 217-

  Wills, Shannon M ^a   Zekman, Richard ^a   Bestul, Daniel ^a   Kuwajerwala, Nafisa ^a   Decker, David ^a  

^a BEAUMONT HOSPITAL   (United States)

Author keywords

breast cancer; gastrectomy; malabsorption; Roux en Y gastric bypass; tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CARCINOMA; BYPASS SURGERY; CANCER RADIOTHERAPY; CASE REPORT; CASE STUDY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; MALABSORPTION; MORBID OBESITY; PARTIAL MASTECTOMY; ROUX Y ANASTOMOSIS; STEADY STATE; STOMACH BYPASS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; FEMALE; GASTRIC BYPASS; HUMANS; INTESTINAL ABSORPTION; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TAMOXIFEN;

EID: 75849137370     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1592/phco.30.2.217     Document Type: Review

References (30)

1. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: A systematic review and meta-analysis. J Am Med Assoc. 2004;292:1724-1737
2. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176-2183
3. Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm. 2006;63:1852-1857
4. Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the united states-no statistically significant change since 2003-2004. NCHS Data Brief. 2007:1-8
5. Ponsky TA, Brody F, Pucci E. Alterations in gastrointestinal physiology after roux-en-y gastric bypass. J Am Coll Surg. 2005;201:125-131
6. Kral JG, Brolin RE, Buchwald H, Pories WJ, Sarr MG, Sugerman HJ, Wolfe BM. Research considerations in obesity surgery. Obes Res. 2002;10:63-64
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of u.S. Adults. N Engl J Med. 2003;348:1625-1638
8. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998;339:1609-1618
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96
10. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of us women. Cancer Causes Control. 2002;13:325-332
11. van den Brandt PA, Spiegelman D, Yaun SS, Adami HO, Beeson L, Folsom AR, Fraser G, Goldbohm RA, Graham S, Kushi L, Marshall JR, Miller AB, Rohan T, Smith-Warner SA, Speizer FE, Willett WC, Wolk A, Hunter DJ. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol. 2000;152:514-527
12. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane Database Syst Rev. 2005; 1-145
13. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH, Nguyen NT, Li Z, Mojica WA, Hilton L, Rhodes S, Morton SC, Shekelle PG. Meta-analysis: Surgical treatment of obesity. Ann Intern Med. 2005;142:547-559
14. Gastrointestinal surgery for severe obesity: National institutes of health consensus development conference statement. Am J Clin Nutr. 1992 55 615S-619S
15. Colquitt J, Clegg A, Loveman E, Royle P, Sidhu MK. Surgery for morbid obesity. Cochrane Database Syst Rev. 2005:1-145
16. Alvarez-Leite JI. Nutrient deficiencies secondary to bariatric surgery. Curr Opin Clin Nutr Metab Care. 2004;7:569-575
17. Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med. 2007;20:310-313
18. Sobieraj DM, Wang F, Kirton OC. Warfarin resistance after total gastrectomy and roux-en-y esophagojejunostomy. Pharmacotherapy. 2008;28:1537-1541
19. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39:215-231
20. Malone M. Altered drug disposition in obesity and after bariatric surgery. Nutr Clin Pract. 2003;18:131-135
21. Macgregor AM, Boggs L. Drug distribution in obesity and following bariatric surgery: A literature review. Obes Surg. 1996;6:17-27
22. Chu E, DeVita V. Cancer chemotherapy drug manual. Salisbury: Jones and Bartlett; 2007.
23. Kisanga ER, Gjerde J, Guerrieri-Gonzaga A, Pigatto F, Pesci-Feltri A, Robertson C, Serrano D, Pelosi G, Decensi A, Lien EA. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial. Clin Cancer Res. 2004;10:2336-2343
24. Buckley MM, Goa KL. Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs. 1989;37:451-490
25. Astra zeneca pharmaceuticals, product information nolvadex® (tamoxifen citrate). 2003.
26. Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, Williams CJ. A comparison of two doses of tamoxifen (nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer. 1984;50:199-205
27. Tormey DC, Simon RM, Lippman ME, Bull JM, Myers CE. Evaluation of tamoxifen dose in advanced breast cancer: A progress report. Cancer Treat Rep. 1976;60:1451-1459
28. Stewart JF, Minton MJ, Rubens RD. Trial of tamoxifen at a dose of 40 mg daily after disease progression during tamoxifen therapy at a dose of 20 mg daily. Cancer Treat Rep. 1982;66:1445-1446
29. Ingle JN, Suman VJ, Rowland KM, Mirchandani D, Bernath AM, Camoriano JK, Fishkin PA, Nikcevich DA, Perez EA. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North central cancer treatment group trial n0032. J Clin Oncol. 2006;24:1052-1056
30. Punglia RS, Burstein HJ, Winer EP, Weeks JC. Pharmacogenomic variation of cyp2d6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis. J Natl Cancer Inst. 2008;100:642-648